These observations supported our hypothesis that treating 4T1 tumor cells with BSA-FITC-Man@Mn2+-Ft@Lap could substantially enhance their immunogenicity through releasing abundant DAMPs, which may facilitate the subsequent activation of tumor-specific CD4 and CD8 T cells for enhancing the antitumor immune response. The gene discussed is CD4; the disease is neoplasm.